Galmed 1-Year Results Of The Open-Label Part Of Its Global Phase 3 Trial Of Aramchol In 150 Patients With NASH And Fibrosis Have Been Published In Hepatology
Portfolio Pulse from Benzinga Newsdesk
Galmed Pharmaceuticals has published the one-year results of its Phase 3 trial of Aramchol, showing significant anti-fibrotic effects in patients with NASH and fibrosis. The study, involving 150 patients, was published in Hepatology.
September 25, 2024 | 12:21 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Galmed Pharmaceuticals' Phase 3 trial results for Aramchol demonstrate significant anti-fibrotic effects in NASH patients, potentially boosting investor confidence and stock price.
The publication of positive Phase 3 trial results for Aramchol in a reputable journal like Hepatology is likely to increase investor confidence in Galmed Pharmaceuticals. The significant anti-fibrotic effects demonstrated in the trial could lead to increased interest in the company's stock, potentially driving the price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100